SG Americas Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

SG Americas Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-46,700	Closed	-$4K	–	3247
2025 Q4	$4K	Hold	46,700	–	–	﹤0.01%	3544
2025 Q3	$25K	Hold	46,700	–	–	﹤0.01%	3268
2025 Q2	$63K	Hold	46,700	–	–	﹤0.01%	2731
2025 Q1	$398K	Sell	46,700 -10,000	-18%	-$673K	﹤0.01%	1966
2024 Q4	$404K	Buy	+56,700	New	+$3.8M	﹤0.01%	1526
2018 Q1	–	Sell	-71,100	Closed	-$66K	–	3254
2017 Q4	$66K	Hold	71,100	–	–	﹤0.01%	2933
2017 Q3	$334K	Buy	+71,100	New	+$6.28M	﹤0.01%	2146
2017 Q1	–	Sell	-14,000	Closed	-$4K	–	3277
2016 Q4	$4K	Hold	14,000	–	–	﹤0.01%	3048
2016 Q3	$34K	Hold	14,000	–	–	﹤0.01%	3212
2016 Q2	$21K	Hold	14,000	–	–	﹤0.01%	2507
2016 Q1	$49K	Hold	14,000	–	–	﹤0.01%	2767
2015 Q4	$195K	Buy	+14,000	New	+$1.46M	﹤0.01%	2120
2015 Q3	–	Sell	-14,000	Closed	-$489K	–	2123
2015 Q2	$489K	Hold	14,000	–	–	﹤0.01%	1459
2015 Q1	$385K	Buy	+14,000	New	+$1.48M	﹤0.01%	1562

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG Americas Securities's BMRN Position: Q1 2026 in Review

SG Americas Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 59% in Q1 2026, selling an estimated $12.3M and leaving 146,963 shares worth $8.3M. The position accounts for 0.01% of the portfolio, ranked #852.

SG Americas Securities first reported a position in BMRN in Q3 2013 and has held it in 49 quarters since. The position peaked at $21.3M in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

SG Americas Securities held 146,963 shares of BioMarin Pharmaceuticals worth $8.3M as of Q1 2026.
SG Americas Securities sold 211,415 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $12.3M.
BioMarin Pharmaceuticals made up 0.01% of SG Americas Securities's portfolio in Q1 2026, its #852 holding.
SG Americas Securities first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
SG Americas Securities's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2025.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.